Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

remedyrepack inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. hypothalamic-pituitary-adrenal (hpa) axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere with the growth and development of children.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Malta - anglų - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - betamethasone valerate - cutaneous solution - betamethasone valerate 0.1 % (w/w) - corticosteroids, dermatological preparations

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

vedco, inc. - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 0.57 mg in 1 ml - indications: for the treatment of infected superficial lesions in dogs caused by bacteria susceptible to gentamicin. contraindications: if hypersensitivity of any of the components occurs, discontinue treatment and institute appropriate therapy.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

vedco - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 0.57 mg in 1 ml - indications : for the treatment of infected superficial lesions in dogs caused by bacteria sensitive to gentamicin. contraindications : if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

mwi - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 0.57 mg in 1 ml - indications : for the treatment of infected superficial lesions in dogs caused by bacteria sensitive to gentamicin. contraindications : if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - betamethasone valerate 0.122%{relative} equivalent to 0.1% betamethasone - lotion - 0.1 % - active: betamethasone valerate 0.122%{relative} equivalent to 0.1% betamethasone excipient: cetomacrogol 1000 cetostearyl alcohol citric acid monohydrate glycerol isopropyl alcohol liquid paraffin methyl hydroxybenzoate purified water sodium citrate dihydrate xanthan gum - betnovate lotion is a potent topical corticosteroid indicated foradults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses. these include the following: ·atopic dermatitis (including infantileatopic dermatitis) ·nummular dermatitis (discoid eczema) ·prurigo nodularis ·psoriasis (excluding widespread plaque psoriasis) ·lichen simplex chronicus (neurodermatitis) and lichen planus ·seborrhoeic dermatitis ·irritant or allergic contact dermatitis ·discoid lupus erythematosus ·insect bite reactions ·miliaria (prickly heat); and ·adjunct to systemic steroid therapy in generalised erythroderma.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - betamethasone valerate, quantity: 0.244 mg/g - cream - excipient ingredients: purified water; sodium hydroxide; chlorocresol; cetostearyl alcohol; cetomacrogol 1000; phosphoric acid; white soft paraffin; liquid paraffin; monobasic sodium phosphate dihydrate - indications as at 30 april 1991: for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as atopic eczema, infantile eczema, nummular eczema, anogenital and senile pruritus, contact dermatitis, seborrhoeic dermatitis, neurodermatitis, solar dermatitis, stasis dermatitis and psoriasis. celestone -m is indicated for maintenance therapy.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

viatris limited - betamethasone valerate 0.1215%{relative} equivalent to betamethasone 0.1% w/w; betamethasone valerate 0.1216%{relative} equivalent to betamethasone 0.1% w/w - topical cream - 0.1% w/w - active: betamethasone valerate 0.1215%{relative} equivalent to betamethasone 0.1% w/w excipient: ceteareth-20 cetostearyl alcohol chlorocresol liquid paraffin monobasic sodium phosphate dihydrate purified water sodium hydroxide white soft paraffin active: betamethasone valerate 0.1216%{relative} equivalent to betamethasone 0.1% w/w excipient: ceteareth-20 cetostearyl alcohol chlorocresol liquid paraffin monobasic sodium phosphate dihydrate purified water sodium hydroxide white soft paraffin - beta preparations are indicated for the treatment of: eczema, including atopic, infantile and discoid eczemas, prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses, including lichen simplex, lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus; insect bite reactions; prickly heat; and they may be used as an adjunct to systemic steroid therapy in generalised erythroderma.